Success Metrics

Active Trials
2(40%)

Phase Distribution

Ph phase_2
3
60%
Ph phase_3
1
20%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Other(3)

Detailed Status

unknown3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 23 (60.0%)
Phase 31 (20.0%)

Trials by Status

recruiting240%
unknown360%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_2

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

NCT05765877
unknownphase_3

Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

NCT04632758
recruitingphase_2

WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC

NCT05351320
unknownphase_2

A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer

NCT04641754
unknownphase_1

A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients

NCT03389815

Clinical Trials (5)

Showing 5 of 5 trials
NCT05765877Phase 2

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

Recruiting
NCT04632758Phase 3

Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Unknown
NCT05351320Phase 2

WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC

Recruiting
NCT04641754Phase 2

A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer

Unknown
NCT03389815Phase 1

A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5